NewGenIvf Group Financials

NewGenIvf Group (NIVF) reported $4.7M in total revenue for fiscal year 2025. This represents a -13.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

NewGenIvf Group (NIVF) revenue declined by 13% year-over-year, from $5.4M to $4.7M in fiscal year 2025.

Yes, NewGenIvf Group (NIVF) reported a net income of $9.9M in fiscal year 2025, with a net profit margin of 209.0%.

NewGenIvf Group (NIVF) reported diluted earnings per share of $3.04 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

NewGenIvf Group (NIVF) had EBITDA of -$10.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

NewGenIvf Group (NIVF) had a gross margin of 20.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

NewGenIvf Group (NIVF) had an operating margin of -226.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

NewGenIvf Group (NIVF) had a net profit margin of 209.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

NewGenIvf Group (NIVF) has a return on equity of 37.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

NewGenIvf Group (NIVF) generated -$11.1M in free cash flow during fiscal year 2025. This represents a -33.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

NewGenIvf Group (NIVF) generated -$10.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

NewGenIvf Group (NIVF) had $32.7M in total assets as of fiscal year 2025, including both current and long-term assets.

NewGenIvf Group (NIVF) invested $135K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

NewGenIvf Group (NIVF) had 240,622 shares outstanding as of fiscal year 2025.

NewGenIvf Group (NIVF) had a current ratio of 3.12 as of fiscal year 2025, which is generally considered healthy.

NewGenIvf Group (NIVF) had a debt-to-equity ratio of 0.25 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

NewGenIvf Group (NIVF) had a return on assets of 30.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2025 data, NewGenIvf Group (NIVF) had $759K in cash against an annual operating cash burn of $10.9M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

NewGenIvf Group (NIVF) has an Altman Z-Score of -0.00, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

NewGenIvf Group (NIVF) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

NewGenIvf Group (NIVF) has an earnings quality ratio of -1.11x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

NewGenIvf Group (NIVF) has an interest coverage ratio of -17.4x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

NewGenIvf Group (NIVF) scores 32 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.